Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Adagene Announces First Patient Dosed in Phase 1 Trial of Muzastotug Combination for Colorectal Cancer

By Public Technologies
  • Adagene dosed the first patient in a Phase 1 trial testing muzastotug with Incyte’s INCA33890 for microsatellite stable colorectal cancer.
  • The open-label dose-escalation and expansion study targets third-line patients with or without liver metastases whose disease progressed on prior therapies.
  • The trial will assess whether combining the masked anti-CTLA-4 therapy with the TGFβR2 × PD-1 bispecific antibody improves responses with acceptable safety.
  • Under the collaboration announced in April 2026, Incyte sponsors and conducts the study; Adagene supplies muzastotug.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280700PRIMZONEFULLFEED9851867) on October 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.